Glaukos to Spotlight Interventional Glaucoma Advances at ESCRS 2025

Sponsored by Glaukos

Micro solutions, macro impact. Glaukos puts Trabecular Micro-Bypass (TMB) technologies in the spotlight at the ESCRS 2025. 

With Copenhagen calling and the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2025) underway, Glaukos is prepared to showcase its latest technologies in micro-invasive trabecular micro- bypass (TMB). Attendees can expect a full slate of expert-led sessions highlighting the iStent inject^® W and the next-generation iStent infinite^®, with insights that bridge evidence-based outcomes and real-world experience. 

Both products have received Medical Device Regulation (MDR) certification, a robust framework established to ensure high standards of quality, safety and effectiveness for medical devices marketed in the EU. 

Evolution…or revolution?

The centerpiece of Glaukos’s presence at ESCRS 2025 will be a symposium provocatively titled iStent infinite^®: Evolution or Revolution? Chaired by renowned ophthalmologist Dr. Ike Ahmed (Canada), the session will take place Saturday, September 13, from 13:00 to 14:00 in Auditorium 11. 

Kicking off the symposium, Dr. Sev Teymoorian (USA) will set the stage with a look at interventional glaucoma in practice. Dr. Kevin Gillmann (Switzerland) will then discuss trabecular micro-bypass as a truly micro-invasive and safe technology. Dr. Imran Masood (UK) will follow with a preview of the next-generation injector system. 

To round out the hour, Dr. Henny Beckers (Netherlands) will walk through clinical data on the iStent infinite^®, while Dr. Ahmed will share practical insights from his experience using the technology in real-world cases. 

From clinical data to daily practice

Beyond the symposium, Glaukos will offer a full program of presentations at their booth (E154, Hall E), providing attendees with opportunities to dive deeper into products’ performance and procedural best practices. 

Saturday’s booth program includes:

Sunday’s schedule features:

The iStent inject^® W

Still widely regarded as the trabecular micro-bypass benchmark, the iStent inject^® W is based on the iStent^® technologies with more than 20 years of clinical evidence, supported by over 300 peer-reviewed publications and with more than 1 million stent devices implanted worldwide. Designed for implantation during cataract surgery or as a standalone procedure, the device targets mild to moderate primary open-angle glaucoma by bypassing the trabecular meshwork, the primary site of outflow resistance. 

The two-stent system enhances access to multiple collector channels by positioning the stents two to three clock hours apart. Its overall safety profile is similar to cataract surgery alone¹, offering a tissue-sparing approach that preserves future surgical options. 

The iStent infinite^®

For patients with moderate to advanced glaucoma, the iStent infinite^® offers a next-generation option with broader therapeutic reach. Featuring three preloaded stents, the system aims to simplify implantation and enhance outcomes. 

The new next generation injector system includes several design updates: 

• A stent delivery button for controlled deployment
• Auto-retracting introducer tip to minimize viscoelastic loss
• Eight-degree angled tube for better access through corneal incisions
• Visualization windows and ergonomic grip for enhanced control

According to Glaukos, the system addresses a critical treatment gap: even patients who appear “controlled” may still be at risk for significant disease progression. Of note, one study in Ophthalmology found a 13.5% risk of unilateral blindness and 4.3% bilateral within 20 years, with an average time to blindness of just under six years.² 

In a 12-month pivotal trial of patients with two or more prior failed filtering surgeries, iStent infinite^® demonstrated³: 

• 81.8% of patients achieved ≥20% reduction in IOP
• 53% of patients achieved ≥30% reduction in IOP
• 93% of eyes were on the same or fewer medications at month 12
• No reported cases of hypotony, explants, cyclodialysis clefts or device-related interventions

The high-tech helping hand

Complementing these stent technologies is the iprism^® SX gonioscopy lens, developed to improve visualization and control during stent placement. Its bionic optic offers both a wide anterior chamber view and magnified view of the angle, while its ergonomic handle and stabilizers aid in maintaining a steady hand throughout the procedure. 

A commitment to advancing glaucoma care

By spotlighting these technologies at ESCRS 2025, Glaukos reinforces its role in shaping the future of interventional glaucoma care. The company’s focus on minimally invasive, tissue-preserving solutions aligns with a broader shift toward earlier, personalized glaucoma management, especially for patients who may benefit from intervention before functional vision is compromised. 

For attendees seeking practical tools to improve long-term outcomes in glaucoma care, the Glaukos symposium and booth program offer a chance to hear from the experts…and maybe pick up a few pearls while they’re at it. 

Because when it comes to glaucoma, a little intervention now might mean a lot more vision later. 

 Editor’s Note: This content is intended exclusively for healthcare professionals. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all countries.

References

1. Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al.; iStent inject Study Group. Prospective, Randomized, Controlled Pivotal Trial of an Ab Interno Implanted Trabecular Micro-Bypass in Primary Open-Angle Glaucoma and Cataract: Two-Year Results. Ophthalmology. 2019;126(6):811-821.
2. Malihi M, Moura Filho ER, Hodge DO, Sit AJ. Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota. Ophthalmology. 2014;121(1):134-141.
3. Sarkisian SR Jr, Grover DS, Gallardo MJ, et al; iStent infinite Study Group. Effectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma. J Glaucoma. 2023;32(1):9-18.

iStent^® IMPORTANT SAFETY INFORMATION

INDICATIONS FOR USE: The iStent® Trabecular Micro-Bypass System is intended to reduce intraocular pressure safely and effectively in patients diagnosed with primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma. The device is safe and effective when implanted in combination with cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction. The device may also be implanted in patients who continue to have elevated intraocular pressure despite prior treatment with glaucoma medications and conventional glaucoma surgery.

CONTRAINDICATIONS: The iStent® Trabecular Micro-Bypass Stent is contraindicated under the following circumstances or conditions: • In eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations • In patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. 

WARNINGS/PRECAUTIONS: For prescription use only. This device has not been studied in patients with uveitic glaucoma. Do not use the devices if the Tyvek® lid has been opened or the packaging appears damaged. In such cases, the sterility of the device may be compromised. iStent is MR-Conditional. Physician training by Glaukos personnel is required prior to use of this device. Do not re-use the stent(s) or inserter, as this may result in infection and/or intraocular inflammation, as well as occurrence of potential postoperative adverse events. There are no known compatibility issues with the iStent and other intraoperative devices (e.g., viscoelastics) or glaucoma medications. Unused product & packaging may be disposed of in accordance with facility procedures. Implanted medical devices and infected products must be disposed of as medical waste.

iStent inject® W IMPORTANT SAFETY INFORMATION

INDICATIONS FOR USE: The iStent inject® W, is intended to reduce intraocular pressure safely and effectively in patients diagnosed with primary openangle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma. The iStent inject® W, can deliver two (2) stents on a single pass, through a single incision. The implant is designed to stent open a passage through the trabecular meshwork to allow for an increase in the facility of outflow and a subsequent reduction in intraocular pressure. The device is safe and effective when implanted in combination with cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction. The device may also be implanted in patients who continue to have elevated intraocular pressure despite prior treatment with glaucoma medications and conventional glaucoma surgery. CONTRAINDICATIONS: The iStent inject® W System is contraindicated under the following circumstances or conditions: • In eyes with primary angle closure glaucoma, or secondary angle closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations. • In patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. 

WARNINGS/PRECAUTIONS: • For prescription use only. • This device has not been studied in patients with uveitic glaucoma. • Do not use the device if the Tyvek® lid has been opened or the packaging appears damaged. In such cases, the sterility of the device may be compromised. • Due to the sharpness of certain injector components (i.e. the insertion sleeve and trocar), care should be exercised to grasp the injector body. Dispose of device in a sharps container. • iStent inject® W is MR Conditional. • Physician training is required prior to use of the iStent inject® W System. • Do not re-use the stent(s) or injector, as this may result in infection and/or intraocular inflammation, as well as occurrence of potential postoperative adverse events. • There are no known compatibility issues with the iStent inject® W and other intraoperative devices. (e.g., viscoelastics) or glaucoma medications. • Unused product & packaging may be disposed of in accordance with facility procedures. Implanted medical devices and contaminated products must be disposed of as medical waste. • The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should consider an appropriate treatment regimen to reduce intraocular pressure. • Patients should be informed that placement of the stents, without concomitant cataract surgery in phakic patients, can enhance the formation or progression of cataract. 

ADVERSE EVENTS: Please refer to Directions For Use for additional adverse event information. CAUTION: Please reference the Directions For Use labelling for a complete list of contraindications, warnings and adverse events.

iStent infinite® IMPORTANT SAFETY INFORMATION

INDICATION FOR USE: The iStent infinite System is intended to reduce intraocular pressure safely and effectively in adult patients diagnosed with primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma. The device is safe and effective when implanted in combination with or without cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction. The device may also be implanted in patients who continue to have elevated intraocular pressure despite prior treatment with glaucoma medications and/or conventional glaucoma surgery. 

CONTRAINDICATIONS: The iStent infinite System is contraindicated under the following circumstances or conditions: •In eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations.• In patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

WARNINGS/PRECAUTIONS: •For prescription use only. • Intended users are trained ophthalmologists only. • This device has not been studied in patients with uveitic glaucoma. • Do not use the device if the Tyvek® lid has been opened or the packaging appears damaged. In such cases, the sterility of the device may be compromised. • Due to the sharpness of certain injector components (i.e., the insertion sleeve and trocar), care should be exercised to grasp the injector body. Dispose of device in a sharps container. • iStent infinite is MR-Conditional • Physician training is required prior to use of the iStent infinite System. • Do not re-use the stent(s) or injector, as this may result in infection and/or intraocular inflammation, as well as occurrence of potential postoperative adverse events • There are no known compatibility issues with theiStent infinite and other intraoperative devices (e.g., viscoelastics) or glaucoma medications. • Unused product & packaging may be disposed of in accordance with facility procedures. Implanted medical devices and contaminated products must be disposed of as medical waste. • The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should consider an appropriate treatment regimen to reduce intraocular pressure. • Patients should be informed that placement of the stents, without concomitant cataract surgery in phakic patients, can enhance the formation or progression of cataract. ADVERSE EVENTS: The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%). CAUTION: Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

iprism® SX DIRECTIONS FOR USE:

See iprism® SX package insert for detailed instructions.

Glaukos^®, iStent^®, iStent inject^® W, iStent infinite^® and iprism^® SX are registered trademarks of Glaukos Corporation.

All rights reserved. ©2025. PM-EU-0368